Our Work in Nephrology

Renal patients are among the most challenging to manage due to multiple co-morbidities and poor outcomes. Nephrologists see a wide array of patients including those across all five stages of chronic kidney disease, those on dialysis and those with kidney transplants. At Spherix, we have an intimate understanding of the US dialysis market, unparalleled perspective on hospital-based nephrology practice and a unique glimpse into the patient flow within private practice nephrology.

VIEW REPORTS OFFERED IN THIS AREA

Diseases Covered

Renal Anemia, Chronic Kidney Disease, Dialysis, Diabetic Nephropathy, Hyperkalemia, Hyperphosphatemia, Renal Anemia, SHPT and Lupus Nephritis.

Board of Advisors

Coming soon.

Advocacy Groups

The primary objectives of advocacy groups are to educate, advocate, collaborate, and improve the efficiency of services for individuals with disease in nephrology and those who are close to them.

RECENT PUBLICATIONS

Amgen’s Parsabiv Starts to Gain Ground in US Dialysis Market with the Nephrology User Base Expected to Climb from 20% to Over 80% Within the Next Six Months – February 1, 2018
>VIEW ARTICLE

Cardiologists Continue to Lag Nephrologists When It Comes to the Adoption of Vifor/Relypsa’s Veltassa for Hyperkalemia, but Prescribers in Both Specialties Report Mounting Market Access Pressure – November 16, 2017
>VIEW ARTICLE

In the CKD-MBD Market, OPKO’s Rayaldee Continues to Struggle While Keryx’s Auryxia Gains Momentum, According to Latest Quarterly Update from Spherix Global Insights – November 14, 2017
>VIEW ARTICLE

The Renal Anemia Market is on the Cusp of Change Beginning with the FDA Approval of Keryx Biopharmaceutical’s Auryxia for the Treatment of Iron Deficiency Anemia (IDA) in Adults with Chronic Kidney Disease, Not on Dialysis (CKD-ND) – November 7, 2017
>VIEW ARTICLE

UPCOMING CONFERENCES

American Society of Nephrology 2017 Conference
>LEARN MORE